|Bid||0.0000 x 900|
|Ask||2.4900 x 1300|
|Day's Range||2.2700 - 2.4350|
|52 Week Range||2.0100 - 11.5500|
|Beta (3Y Monthly)||4.20|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).
Mallinckrodt (MNK) recruits the first patient in a mid-stage study on MNK-6106 for the treatment of hepatic cirrhosis and hepatic encephalopathy.
Regeneron's (REGN) study on four investigational therapies for Ebola virus infection is stopped early as its therapy, REGN-EB3, was superior to Mapp Biopharmaceutical Inc.'s ZMapp in preventing death.
The clinical-stage biotech continued to conserve cash while conducting multiple clinical studies in the second quarter.
Celldex (CLDX) delivered earnings and revenue surprises of 28.21% and -43.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Celldex (CLDX) presents updated data on CDX-3379 and Erbitux combination regimen, which supports further development in biomarker selected patient population.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Array Biopharma ...
After two successive weeks of losses, biotech stocks slowly clawed back. Multiple conference presentations, independent clinical trial readouts and a few FDA decisions marked the key events in the biotech ...
The following companies are falling knives since their share prices have declined more than 59% over the past year through May 13. Wall Street issued a recommendation rating of overweight to buy for all three stocks, increasing the likelihood of them outperforming the S&P 500 index within 52 weeks. Warning! GuruFocus has detected 5 Warning Signs with CLDX.
The clinical-stage biotech effectively conserved cash in the first quarter, thanks to cost cuts following last year's pipeline setback with experimental cancer drug glemba.
Celldex (CLDX) delivered earnings and revenue surprises of 0.88% and 13.10%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Hampton, New Jersey-based company said it had a loss of $1.40. Losses, adjusted for asset impairment costs and non-recurring costs, came to $1.13 per share. The biopharmaceutical ...
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The clinical-stage biotech stretched out its cash in the fourth quarter by cost reductions and took the necessary moves in the following months to retain its listing on the Nasdaq stock exchange.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on March 6) Chiasma Inc (NASDAQ: CHMA ) Magenta Therapeutics Inc ...
In the latest trading session, Celldex Therapeutics (CLDX) closed at $5.92, marking a -1.17% move from the previous day.